Results are delivered in 30-180 minutes compared to 24-72 hours for traditional cultures.
Faster rule-out of negative samples reduces culture volume and rework, freeing staff time and resources while maintaining clinical integrity and improving lab throughput.
Reporting can be integrated into your LIS/EMR through an LIS2-A2 compliant interface.
In many workflows, BacterioScan serves as a front-line screening tool, allowing you to reserve culture only for positives, dramatically improving efficiency.

BacterioScan delivers 97.7% sensitivity and has a 99.2% negative predictive value, providing a reliable clinical confidence, particularly in ruling out negative UTIs quickly.
BacterioScan is the ONLY test FDA-cleared to rule out a UTI on the same day.
FDA considered samples as "UTI positive" with: >50,000 CFU/mL and any of the 22 UTI pathogens.
FDA Common UTI Pathogens:
·       Escherichia coli
·       Klebsiella pneumoniae
·       Proteus mirabilis
·       Enterobacter cloacae
·       Pseudomonas aeruginosa
·       Enterococcus faecalis
·       Enterococcus faecium
·       Staphylococcus aureus
·       Staphylococcus saprophyticus
·       Streptococcus agalactiae
Rare UTI Pathogens:
·       Acinetobacter baumannii
·       Citrobacter freundii/koseri
·       Morganella morganii
·       Aerococcus urinae/viridans
·       Actinobaculum schaalii
·       Coryebacterium striatum
·       Corynebacterium urealyticum

BacterioScan reduces costs by lowering labor requirements, reducing consumables, minimizing materials, decreasing the number of visits, and supporting better antibiotic stewardship.
The test is reimbursable, with a strong adoption and favorable reimbursement rates from many payors.
Faster patient throughput, labor savings, favorable reimbursements, and lower material costs.

Frequently Asked Questions